Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan
- 1 June 2002
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 30 (6) , 731-733
- https://doi.org/10.1124/dmd.30.6.731
Abstract
Irinotecan or CPT-11 [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] is a derivative of camptothecine used in the treatment of advanced colorectal cancer. It requires activation to SN-38 (7-ethyl-10-hydroxycamptothecine) by carboxylesterase. Irinotecan and SN-38 are detoxified through two major metabolic pathways: the first one leads to oxidative degradation compounds, APC [7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecine] and NPC [7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecine], and involves cytochrome P450 (3A4 isoform); the second one leads to SN-38 glucuronide (SN-38G) and involves UDP-glucuronosyltransferase (UGT). Using human hepatic microsomes, we studied the interactions of 15 drugs of common use in colorectal cancer patients on these metabolic pathways. Only nifedipine had a significant effect on SN-38 formation, decreasing carboxylesterase activity by 50% at 100 μM and 35% at 10 μM. Three drugs had a significant effect on SN-38G formation: clonazepam increased UGT activity by 50% at 100 μM and 30% at 10 μM, and nifedipine and vinorelbine inhibited the activity by 65 and 55% at 100 μM, respectively, with no effect at 10 μM. Five drugs exerted a significant inhibition on SN-38 formation at 100 μM: clonazepam (70%), methylprednisolone (50%), nifedipine (80%), omeprazole (85%), and vinorelbine (100%). Only omeprazole and vinorelbine still exerted a significant inhibition at 10 μM (30 and 90%, respectively), whereas only vinorelbine had a significant effect at 2 and 0.5 μM (70 and 40%, respectively). In conclusion, potential clinical interactions with the metabolism of irinotecan are likely to be important for vinorelbine, which strongly inhibits irinotecan catabolism by CYP3A4 at clinically relevant concentrations, but not for the other drugs, which exert an effect at concentrations not achievable in patients.Keywords
This publication has 15 references indexed in Scilit:
- Glucuronidation of 7-Ethyl-10-hydroxycamptothecin (SN-38) by the Human UDP-Glucuronosyltransferases Encoded at the UGT1 LocusBiochemical and Biophysical Research Communications, 1999
- CYTOCHROME P-450 3A4: Regulation and Role in Drug MetabolismAnnual Review of Pharmacology and Toxicology, 1999
- Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by Human Liver CarboxylesterasePublished by Elsevier ,1999
- Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissuePublished by Elsevier ,1998
- Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.Journal of Clinical Investigation, 1998
- The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes Differential hydrolysis for the lactone and carboxylate formsNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1997
- Glucuronidation of SN‐38, the Active Metabolite of Irinotecan, by Human Hepatic MicrosomesBasic & Clinical Pharmacology & Toxicology, 1997
- Identification and kinetics of a ?-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecanCancer Chemotherapy and Pharmacology, 1995
- Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1994
- Comparison of Caffeine Metabolism by Slices, Microsomes and Hepatocyte Cultures from Adult Human LiverXenobiotica, 1989